Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Alexion AstraZeneca Rare Disease Completes Acquisition of LogicBio | Contract Pharma

What are you searching for?

Sign in
Breaking News

Alexion AstraZeneca Rare Disease Completes Acquisition of LogicBio

Creates an opportunity to accelerate Alexion’s genomic medicines growth with unique technology, a rare disease R&D team, and preclinical development expertise.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Alexion AstraZeneca Rare Disease has completed its acquisition of LogicBio Therapeutics, Inc., a pioneering genomic medicine company, for $2.07 per share.
 
The acquisition creates an opportunity to accelerate Alexion’s growth in genomic medicines through unique technology, an experienced rare disease R&D team, and expertise in preclinical development. Frederic Chereau, CEO of LogicBio, will join Alexion as Senior Vice President, Strategy and Business Development.
 
LogicBio becomes a wholly owned subsidiary of Alexion. Alexion will retain LogicBio employees at their current location in Lexington, MA.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics